// App-Quantinova.ai

3829 : Preclinical development of a combination inhibitor strategy to block K-Ras effector signaling and autophagy for pancreatic cancer treatment

Researchers

Presenter

  • Kirsten L. Bryant

Principal Investigators

  • Tikvah K. Hayes

  • Daniel Zeitouni

  • Samuel D. George

  • Swapnil Kher

  • Ahmed A. Samatar

  • Kris C. Wood

  • Alec C. Kimmelman

  • Channing J. Der

Medical Centers

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • Theramet Biosciences, Princeton Junction, NJ

  • Duke University, Durham, NC

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Pancreatic cancer

  • Solid malignancies

  • Microphthalmia, syndromic, 9

Biomarkers

  • Extracellular signal-regulated kinase

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • chloroquine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved